You are here: Industry Insights > Knight Therapeutics

News List

Knight Therapeutics invests up to $125m in Latin America-focused Moksha8 pharmaceutical-technology
February 20, 2019
Canada-based Knight Therapeutics has announced it has closed a strategic financing agreement of up to $125m with US-headquartered Moksha8....
Knight Therapeutics licences cancer drug from Puma Biotechnology pharmaceutical-technology
January 15, 2019
Canada-based Knight Therapeutics signed an exclusive licence agreement with Puma Biotechnology to commercialise Nerlynx (neratinib) medicine in the country.....
Puma Biotechnology and Knight Therapeutics Enter into Exclusive License Agreement to Commercialize NERLYNX (neratinib) in Canada firstwordpharma
January 13, 2019
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that it has entered into an exclusive License Agreement with Knight Therapeutics Inc. (TSX: GUD) that grants Knight the exclusive right to commercialize NERLYNX® (neratinib) i
Knight Therapeutics and Jaguar Health Announce Strategic Partnership pharmafocusasia
December 03, 2018
Knight Therapeutics Inc., a Canadian-based specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative prescription....
Knight Therapeutics Announces Canadian Regulatory Approval for PROBUPHINE for Opioid Drug Dependence firstwordpharma
April 23, 2018
Knight signed an exclusive distribution and sublicense agreement with Braeburn in February 2016 granting Knight the exclusive right to distribute PROBUPHINE™ in Canada.